$NNVC
NANOVIRICIDES, INC. Stock $nnvc

$nnvc Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000114420415031364 Filed on May 15, 2015

Income Statement

Concept	2015 Q2	2015 Q1	2014 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.050M	$600.0K	$610.0K
YoY Change	-33.96%	-1.64%	-26.51%
% of Gross Profit
Research & Development	$1.390M	$546.5K	$625.7K
YoY Change	-36.82%	-12.67%	-53.96%
% of Gross Profit
Depreciation & Amortization	$140.0K	$51.33K	$50.00K
YoY Change	180.0%	2.66%	-16.67%
% of Gross Profit
Operating Expenses	$2.440M	$1.123M	$1.233M
YoY Change	-35.62%	-8.98%	-43.7%
Operating Profit		-$1.123M	-$1.233M
YoY Change		-8.98%	-43.7%
Interest Expense	$1.830M	$1.920M	$2.726M
YoY Change	-230.71%	-29.55%	231.48%
% of Operating Profit
Other Income/Expense, Net	-$310.0K	$871.6K	$2.557M
YoY Change	106.67%	-65.92%	-271.39%
Pretax Income	-$920.0K	-$251.0K	$1.324M
YoY Change	-82.77%	-118.96%	-135.95%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income			0.0%
Net Earnings	-$920.0K	-$251.0K	$1.324M
YoY Change	-82.77%	-118.96%	-135.95%
Net Earnings / Revenue
Basic Earnings Per Share		$0.00	$0.02
Diluted Earnings Per Share	-$321.7K	-$0.02	-$0.02
COMMON SHARES
Basic Shares Outstanding	57.15M shares	56.94M shares	53.32M shares
Diluted Shares Outstanding		59.61M shares	55.03M shares

Balance Sheet

Concept	2015 Q2	2015 Q1	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$31.47M	$33.92M	$33.27M
YoY Change	-14.25%	1.95%	115.2%
Cash & Equivalents	$31.47M	$33.92M	$33.27M
Short-Term Investments
Other Short-Term Assets	$0.00	$0.00	$1.340M
YoY Change	-100.0%	-100.0%	-12.99%
Inventory
Prepaid Expenses	$214.4K	$308.6K	$1.339M
Receivables
Other Receivables
Total Short-Term Assets	$31.68M	$34.29M	$34.60M
YoY Change	-14.27%	-0.9%	103.55%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.96M	$10.91M	$3.935M
YoY Change	117.63%	177.16%	755.48%
Goodwill
YoY Change
Intangibles	$399.7K	$401.8K	$410.5K
YoY Change	-2.09%	-2.11%
Long-Term Investments
YoY Change
Other Assets	$140.0K	$0.00	$2.000M
YoY Change	-86.0%	-100.0%
Total Long-Term Assets	$12.50M	$11.31M	$6.346M
YoY Change	81.1%	78.21%	621.1%
TOTAL ASSETS
Total Short-Term Assets	$31.68M	$34.29M	$34.60M
Total Long-Term Assets	$12.50M	$11.31M	$6.346M
Total Assets	$44.19M	$45.60M	$40.95M
YoY Change	0.75%	11.36%	129.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$410.0K	$20.00K	$1.000M
YoY Change	-4.65%	-98.0%	14.94%
Accrued Expenses	$28.52K	$125.1K	$207.1K
YoY Change	-68.95%	-39.62%	38.06%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00
YoY Change
Total Short-Term Liabilities	$600.9K	$523.4K	$1.208M
YoY Change	16.06%	-56.67%	-72.6%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$3.887M
YoY Change	-100.0%	-100.0%	16.39%
Other Long-Term Liabilities	$4.620M	$6.350M	$3.820M
YoY Change	-57.77%	66.23%
Total Long-Term Liabilities	$11.80M	$13.22M	$11.79M
YoY Change	-40.92%	12.07%	253.13%
TOTAL LIABILITIES
Total Short-Term Liabilities	$600.9K	$523.4K	$1.208M
Total Long-Term Liabilities	$11.80M	$13.22M	$11.79M
Total Liabilities	$12.40M	$13.74M	$13.00M
YoY Change	-39.48%	5.68%	67.78%
SHAREHOLDERS EQUITY
Retained Earnings	-$54.10M	-$53.18M	-$44.90M
YoY Change	4.24%	18.44%
Common Stock	$57.24K	$57.15K	$54.54K
YoY Change	4.8%	4.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$31.79M	$31.86M	$27.95M
YoY Change
Total Liabilities & Shareholders Equity	$44.19M	$45.60M	$40.95M
YoY Change	0.75%	11.36%	129.03%

Cashflow Statement

Concept	2015 Q2	2015 Q1	2014 Q1
OPERATING ACTIVITIES
Net Income	-$920.0K	-$251.0K	$1.324M
YoY Change	-82.77%	-118.96%	-135.95%
Depreciation, Depletion And Amortization	$140.0K	$51.33K	$50.00K
YoY Change	180.0%	2.66%	-16.67%
Cash From Operating Activities	-$1.250M	-$2.090M	-$1.860M
YoY Change	31.58%	12.37%	8.77%
INVESTING ACTIVITIES
Capital Expenditures	-$1.200M	-$250.0K	-$1.260M
YoY Change	-25.47%	-80.16%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$1.000M	$0.00
YoY Change	-100.0%		-100.0%
Cash From Investing Activities	-$1.200M	$750.0K	-$1.260M
YoY Change	96.72%	-159.52%	26.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	19.44M
YoY Change	-100.0%	-100.0%	353.15%
NET CHANGE
Cash From Operating Activities	-1.250M	-2.090M	-1.860M
Cash From Investing Activities	-1.200M	750.0K	-1.260M
Cash From Financing Activities	0.000	0.000	19.44M
Net Change In Cash	-2.450M	-1.340M	16.32M
YoY Change	-171.22%	-108.21%	932.91%
FREE CASH FLOW
Cash From Operating Activities	-$1.250M	-$2.090M	-$1.860M
Capital Expenditures	-$1.200M	-$250.0K	-$1.260M
Free Cash Flow	-$50.00K	-$1.840M	-$600.0K
YoY Change	-107.58%	206.67%	-64.91%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12300894	USD
CY2014Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6736742	USD
CY2015Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1393982	USD
CY2014Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1239986	USD
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5496756	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	458954	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	458954	USD
CY2015Q1	us-gaap	Assets Assets	45602825	USD
CY2014Q2	us-gaap	Assets Assets	43859995	USD
CY2015Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	23375	USD
CY2014Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	376446	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33919404	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36696892	USD
CY2015Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	308604	USD
CY2014Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	108089	USD
CY2015Q1	us-gaap	Assets Current AssetsCurrent	34294108	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	36954981	USD
CY2014Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	49455	USD
CY2015Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	125054	USD
CY2014Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	91838	USD
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	523429	USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	517739	USD
CY2015Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2014Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5000000	USD
CY2015Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	13218014	USD
CY2014Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	19972953	USD
CY2015Q1	us-gaap	Liabilities Liabilities	13741443	USD
CY2014Q2	us-gaap	Liabilities Liabilities	20490692	USD
CY2015Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	57150	USD
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	54621	USD
CY2015Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	84982686	USD
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	75212888	USD
CY2015Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-53181861	USD
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-51901400	USD
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	31861382	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	23369303	USD
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	45602825	USD
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	85714285	shares
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	85714285	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57150415	shares
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54620993	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2015-03-31
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Central Index Key EntityCentralIndexKey	0001379006
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Trading Symbol TradingSymbol	NNVC
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	57150000	shares
	dei	Entity Registrant Name EntityRegistrantName	NANOVIRICIDES, INC.
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10906912	USD
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2015Q1	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	0	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	50696	USD
CY2015Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	57149	USD
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2000-07-25
CY2015Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	401805	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	408258	USD
CY2015Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	401805	USD
CY2014Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	408258	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	43859995	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	1323854	USD
	us-gaap	Depreciation Depreciation	153996	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	607628	USD
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57150415	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54620993	shares
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2930436	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2274310	USD
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	576173	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1943123	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2352115	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	1233365	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	1122637	USD
	us-gaap	Operating Expenses OperatingExpenses	4873559	USD
	us-gaap	Operating Expenses OperatingExpenses	4626425	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1233365	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1122637	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4873559	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4626425	USD
CY2014Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	54789	USD
CY2015Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	35009	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	78850	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	156035	USD
CY2014Q1	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	143051	USD
CY2015Q1	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	297276	USD
	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	419305	USD
	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	860454	USD
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2557219	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1323854	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-251018	USD
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-251018	USD
	nnvc	Preferred Shares Issued As Compensation PreferredSharesIssuedAsCompensation	70524	USD
	nnvc	Preferred Shares Issued As Compensation PreferredSharesIssuedAsCompensation	205837	USD
	nnvc	Shares And Warrants Issued For Services SharesAndWarrantsIssuedForServices	96751	USD
	nnvc	Shares And Warrants Issued For Services SharesAndWarrantsIssuedForServices	116110	USD
	nnvc	Common Shares Issued For Interest CommonSharesIssuedForInterest	-1502869	USD
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	167954	USD
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	52130	USD
	us-gaap	Depreciation Depreciation	151902	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	6581	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	6453	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	740515	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-150000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5378063	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4956633	USD
	nnvc	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	1585067	USD
	nnvc	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	6463095	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	200515	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-375000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-8256	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-353071	USD
	nnvc	Increase Decrease Prepaid Expenses Or Accounts Payable Related Parties IncreaseDecreasePrepaidExpensesOrAccountsPayableRelatedParties	35469	USD
	nnvc	Increase Decrease Prepaid Expenses Or Accounts Payable Related Parties IncreaseDecreasePrepaidExpensesOrAccountsPayableRelatedParties	-115555	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	2736	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	33215	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3618201	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5564152	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-4618201	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-4564152	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	28602740	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	735626	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6743297	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	29338366	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	6743297	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	19342102	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2777488	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13923245	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33265347	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	nnvc	Stock Warrants Granted To Brokers StockWarrantsGrantedToBrokers	248758	USD
	nnvc	Stock Warrants Granted To Brokers StockWarrantsGrantedToBrokers	0	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Note 1 - Organization and Nature of Business</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">NanoViricides, Inc. (the “Company) was incorporated under the laws of the State of Colorado on July 25, 2000 as Edot-com.com, Inc<b>.</b> which was organized for the purpose of conducting internet retail sales.  On April 1, 2005, Edot-com.com, Inc. was incorporated under the laws of the State of Nevada for the purpose of re-domiciling as a Nevada corporation.  On <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">May 12, 2005</font>, the corporations were merged and Edot-com.com, Inc<b>.,</b> the Nevada corporation, became the surviving entity.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On June 1, 2005, Edot-com.com, Inc. (“ECMM”) acquired Nanoviricide, Inc., a privately owned Florida corporation (“NVI”), pursuant to an Agreement and Plan of Share Exchange (the “Exchange”).  Nanoviricide, Inc. was incorporated under the laws of the State of Florida on May 12, 2005.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Pursuant to the terms of the Exchange, ECMM acquired NVI in exchange for an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80,000,000</font> newly issued shares of ECMM common stock resulting in an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100,000,000</font></font> shares of ECMM common stock issued and outstanding.  NVI then became a wholly-owned subsidiary of ECMM. The ECMM shares were issued to the NVI shareholders on a pro rata basis, on the basis of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,000</font> shares of the Company’s common stock for each share of NVI common stock held by such NVI shareholder at the time of the Exchange.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As a result of the Exchange transaction, the former NVI stockholders held approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80</font>% of the voting capital stock of the Company immediately after the Exchange.  For financial accounting purposes, this acquisition was a reverse acquisition of ECCM by NVI, under the purchase method of accounting, and was treated as a recapitalization with NVI as the acquirer. Accordingly, the financial statements have been prepared to give retroactive effect to May 12, 2005 (date of inception), of the reverse acquisition completed on June 1, 2005, and represent the operations of NVI.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On June 28, 2005, NVI was merged into its parent ECMM and the separate corporate existence of NVI ceased.  Effective on the same date, Edot-com.com, Inc. changed its name to NanoViricides, Inc. and its stock symbol to “NNVC”, respectively.  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">NanoViricides,  Inc. (the “Company”), is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. We are a company with several drugs in various stages of early development. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), an entity owned and controlled by a significant stockholder, to which we have the necessary exclusive, worldwide licenses in perpetuity. The first agreement we executed with TheraCour Pharma on  September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On February 15, 2010, the Company executed an Additional License Agreement with TheraCour.  Pursuant to the Additional License Agreement, the Company was granted exclusive, worldwide licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes.  As consideration for obtaining these exclusive licenses, we agreed to pay a onetime licensing fee equal to 2,000,000 shares <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(adjusted for the 3.5 to 1 reverse split)</font> of the Company’s Series A Convertible Preferred Stock (the “Series A Preferred Stock”).  The Series A Preferred Stock is convertible, only upon sale or merger of the Company, or the sale of or license of substantially all of the Company’s intellectual property, into shares of the Company’s common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock.  The Series A Preferred Stock has a preferred voting preference at the rate of nine votes per share. The Preferred Series A do not contain any rights to dividends, have no liquidation preference, and are not to be amended without the holder’s approval. The <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,000,000</font> shares were valued at the par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,000</font>.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	dei	Entity Incorporation State Country Name EntityIncorporationStateCountryName	Colorado
	us-gaap	Business Acquisition Name Of Acquired Entity BusinessAcquisitionNameOfAcquiredEntity	Edot-com.com, Inc.
	us-gaap	Business Acquisition Date Of Acquisition Agreement1 BusinessAcquisitionDateOfAcquisitionAgreement1	2005-05-12
CY2011Q1	nnvc	Space For Office And Laboratory SpaceForOfficeAndLaboratory	7000	sqft
CY2011Q1	nnvc	Monthly Base Rent MonthlyBaseRent	8695	USD
CY2011Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2011-02-28
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	78255	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	78255	USD
	invest	Investment Warrants Exercise Price InvestmentWarrantsExercisePrice	3.50
	nnvc	Number Of Common Stock To Be Issued Upon Conversion Of Warrants NumberOfCommonStockToBeIssuedUponConversionOfWarrants	51444	shares
CY2015Q1	nnvc	Fair Value Of Common Stock Warrant Issued During Period For Consulting Services FairValueOfCommonStockWarrantIssuedDuringPeriodForConsultingServices	52130	USD
CY2015Q1	us-gaap	Security Deposit SecurityDeposit	0	USD
CY2014Q2	us-gaap	Security Deposit SecurityDeposit	1000000	USD
CY2014Q1	us-gaap	Interest Expense InterestExpense	2725716	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	1920268	USD
	us-gaap	Interest Expense InterestExpense	2972216	USD
	us-gaap	Interest Expense InterestExpense	2412712	USD
CY2015Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	8376336	USD
CY2014Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	3099780	USD
CY2015Q1	nnvc	Office Equipment Gross OfficeEquipmentGross	30048	USD
CY2014Q2	nnvc	Office Equipment Gross OfficeEquipmentGross	30048	USD
CY2015Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	1400	USD
CY2014Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	1400	USD
CY2015Q1	nnvc	Lab Equipment Gross LabEquipmentGross	3893110	USD
CY2014Q2	nnvc	Lab Equipment Gross LabEquipmentGross	3605514	USD
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9405780	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6495242	shares
	nnvc	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2015Q1	us-gaap	Other Assets Current OtherAssetsCurrent	0	USD
CY2014Q2	us-gaap	Other Assets Current OtherAssetsCurrent	150000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	nnvc	Discount On Longterm Convertible Debentures DiscountOnLongtermConvertibleDebentures	419305	USD
	nnvc	Discount On Longterm Convertible Debentures DiscountOnLongtermConvertibleDebentures	860454	USD
	us-gaap	Related Party Transaction Description Of Transaction RelatedPartyTransactionDescriptionOfTransaction	charge its costs (direct and indirect) plus no more than 30% of direct costs
	nnvc	Lab Supplies And Chemicals Fees LabSuppliesAndChemicalsFees	25000	USD
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	2000	USD
CY2015Q1	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	9000000	USD
CY2014Q2	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	4000000	USD
	us-gaap	Fair Value Measurements Significant Assumptions FairValueMeasurementsSignificantAssumptions	a. The common stock price (post-reverse split) was in the range $2.72 to $2.29; b. The calculated weighted average number of shares of common stock in the period; c. A 5.36% premium over the common shares for the voting preferences; d. The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 4.896% to 5.046% of the total; e. The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from March 1, 2013 and a remaining restricted term of 2.08 to 1.92 years; f. 32.61% to 31.42% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 78.63% to 69.38% volatility, 0.674% to 0.47% risk free rate) applied to the converted common.
CY2014Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	72790654	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-44900947	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	27947261	USD
CY2014Q1	us-gaap	Liabilities Liabilities	13002679	USD
CY2014Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	11794495	USD
CY2014Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2014Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2014Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53318736	shares
CY2015Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56941122	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50307984	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56356105	shares
CY2014Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.50
CY2014Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55033023	shares
CY2015Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59607788	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50307984	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59022772	shares
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1152297	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1323854	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1178576	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-947121	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6601163	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4021024	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.02
CY2015Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.02
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.13
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.07
CY2014Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.02
CY2015Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.00
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.13
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.02
CY2014Q1	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-2502430	USD
CY2015Q1	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-696103	USD
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-2740562	USD
CY2014Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	1714286	shares
CY2015Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	2666667	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	2666667	shares
CY2015Q1	us-gaap	Interest Payable Current InterestPayableCurrent	375000	USD
CY2014Q2	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i><u>Reclassifications</u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Certain accounts in the June 30, 2014 financial statements have been reclassified to conform to the current period presentation.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K/A for the fiscal year ended June 30, 2014 filed on February 23, 2015.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q1	nnvc	Prepaid Expenses Related Parties PrepaidExpensesRelatedParties	66100	USD
CY2014Q2	nnvc	Prepaid Expenses Related Parties PrepaidExpensesRelatedParties	0	USD
	us-gaap	Payments For Advance To Affiliate PaymentsForAdvanceToAffiliate	1000000	USD
	us-gaap	Payments For Advance To Affiliate PaymentsForAdvanceToAffiliate	-1000000	USD
	nnvc	Series Preferred Shares Issued For Debenture Interest SeriesPreferredSharesIssuedForDebentureInterest	1152297	USD
	nnvc	Bifurccation Of Embedded Derivative BifurccationOfEmbeddedDerivative	0	USD
	nnvc	Bifurccation Of Embedded Derivative BifurccationOfEmbeddedDerivative	1879428	USD
	nnvc	Issuance Of Series C Debenture For Deposit Received IssuanceOfSeriesCDebentureForDepositReceived	0	USD
	nnvc	Issuance Of Series C Debenture For Deposit Received IssuanceOfSeriesCDebentureForDepositReceived	5000000	USD
	nnvc	Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued For July SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssuedForJuly	181363	USD
	nnvc	Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne	82360	USD
	nnvc	Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services For August StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServicesForAugust	52130	USD
	nnvc	Common Stock Issued During Exercise Of Warrants Value Issues One CommonStockIssuedDuringExerciseOfWarrantsValueIssuesOne	6743297	USD
	nnvc	Common Stock Shares Issued For Payment Of Debenture Interest Value CommonStockSharesIssuedForPaymentOfDebentureInterestValue	1502869	USD
	nnvc	Series Preferred Shares Value Issued For Consulting And Legal Services Rendered SeriesPreferredSharesValueIssuedForConsultingAndLegalServicesRendered	24474	USD
	us-gaap	Debt Instrument Redemption Description DebtInstrumentRedemptionDescription	the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the Redemption). If the Company intends to repurchase the Debenture, and if the closing bid price of the Common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the Redemption Payment, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of Common Stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of Common Stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of Common Stock (the Redemption Warrants, and collectively with (i) (iii), the Redemption Payment). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a shelf registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act.
CY2014Q4	nnvc	Acuisition And Renovation Expenses Of Manufacturing And Lab Facility AcuisitionAndRenovationExpensesOfManufacturingAndLabFacility	4222549	USD
CY2014Q4	nnvc	Closing Costs Of Facility ClosingCostsOfFacility	81230	USD
CY2014Q3	nnvc	Warrants Issued To Purchase Of Common Stock WarrantsIssuedToPurchaseOfCommonStock	1926656	shares
CY2014Q3	nnvc	Aggregate Purchase Price Of Warrants AggregatePurchasePriceOfWarrants	6743297	USD
	us-gaap	Conversion Of Stock Description ConversionOfStockDescription	the converted value to common at a ratio of 1:3.5.

Files In Submission

Name	View Source	Status
0001144204-15-031364-index-headers.html	Edgar Link	pending
0001144204-15-031364-index.html	Edgar Link	pending
0001144204-15-031364.txt	Edgar Link	pending
0001144204-15-031364-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
nnvc-20150331.xml	Edgar Link	completed
nnvc-20150331.xsd	Edgar Link	pending
nnvc-20150331_cal.xml	Edgar Link	unprocessable
nnvc-20150331_def.xml	Edgar Link	unprocessable
nnvc-20150331_lab.xml	Edgar Link	unprocessable
nnvc-20150331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v410164_10q.htm	Edgar Link	pending
v410164_ex31-1.htm	Edgar Link	pending
v410164_ex31-2.htm	Edgar Link	pending
v410164_ex32-1.htm	Edgar Link	pending
v410164_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NNVC
NANOVIRICIDES, INC. Stock $nnvc

2015 Q2 Form 10-Q Financial Statement

#000114420415031364 Filed on May 15, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNVC NANOVIRICIDES, INC. Stock $nnvc

2015 Q2 Form 10-Q Financial Statement

#000114420415031364 Filed on May 15, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNVC
NANOVIRICIDES, INC. Stock $nnvc